282 related articles for article (PubMed ID: 25765543)
1. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.
Lucas CM; Harris RJ; Holcroft AK; Scott LJ; Carmell N; McDonald E; Polydoros F; Clark RE
Leukemia; 2015 Jul; 29(7):1514-23. PubMed ID: 25765543
[TBL] [Abstract][Full Text] [Related]
2. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
Wang J; Huang T; Sun J; Yu Y; Liu Z; Li W; Jia J; Chen C
Med Oncol; 2014 Aug; 31(8):112. PubMed ID: 25023053
[TBL] [Abstract][Full Text] [Related]
3. c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.
Lucas CM; Harris RJ; Giannoudis A; Clark RE
Haematologica; 2015 May; 100(5):e179-82. PubMed ID: 25661443
[No Abstract] [Full Text] [Related]
4. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.
Lucas CM; Harris RJ; Giannoudis A; Copland M; Slupsky JR; Clark RE
Blood; 2011 Jun; 117(24):6660-8. PubMed ID: 21490338
[TBL] [Abstract][Full Text] [Related]
5. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.
Laine A; Sihto H; Come C; Rosenfeldt MT; Zwolinska A; Niemelä M; Khanna A; Chan EK; Kähäri VM; Kellokumpu-Lehtinen PL; Sansom OJ; Evan GI; Junttila MR; Ryan KM; Marine JC; Joensuu H; Westermarck J
Cancer Discov; 2013 Feb; 3(2):182-97. PubMed ID: 23306062
[TBL] [Abstract][Full Text] [Related]
6. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
Mäkelä E; Pavic K; Varila T; Salmenniemi U; Löyttyniemi E; Nagelli SG; Ammunét T; Kähäri VM; Clark RE; Elo LL; Bachanaboyina VK; Lucas CM; Itälä-Remes M; Westermarck J
Clin Cancer Res; 2021 May; 27(10):2848-2860. PubMed ID: 33674272
[TBL] [Abstract][Full Text] [Related]
8. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
9. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
10. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
11. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
Tan Z; Peng A; Xu J; Ouyang M
BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554
[TBL] [Abstract][Full Text] [Related]
12. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
13. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
14. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
15. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
16. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
17. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
Albajar M; Gómez-Casares MT; Llorca J; Mauleon I; Vaqué JP; Acosta JC; Bermúdez A; Donato N; Delgado MD; León J
Mol Cancer Res; 2011 May; 9(5):564-76. PubMed ID: 21460180
[TBL] [Abstract][Full Text] [Related]
18. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
